MDR1 in paroxetine-induced sexual dysfunction
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antidepressive Agents, Second-Generation administration & dosage MeSH
- Bulimia Nervosa drug therapy genetics MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Mutation genetics MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics MeSH
- ATP Binding Cassette Transporter, Subfamily B MeSH
- Polymorphism, Genetic * MeSH
- Sexual Dysfunctions, Psychological chemically induced genetics MeSH
- Case-Control Studies MeSH
- Anxiety Disorders drug therapy genetics MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- ABCB1 protein, human MeSH Browser
- Antidepressive Agents, Second-Generation MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 MeSH
- ATP Binding Cassette Transporter, Subfamily B MeSH
Paroxetine-induced sexual dysfunction represents a frequent treatment complication of otherwise efficient antidepressants. The genetic polymorphism of pharmacokinetic genes may contribute to the occurrence of such dysfunctions. This study presents the effect of MDR1 gene polymorphisms on sexual function in 18 women with bulimia nervosa, 18 women with anxiety disorders, and 19 healthy control subjects. It also deals with the relation between MDR1 gene polymorphisms and paroxetine-induced sexual dysfunction. The results demonstrated that MDR1 G2677T/A gene polymorphism allele carriers treated with paroxetine presented with difficulties with orgasm (p = .008) and lubrication (p < .001).
References provided by Crossref.org
